Form 4: Celldex Therapeutics Director Granted Stock Options
Statement of Changes in Beneficial Ownership
Celldex Therapeutics reports that Director Harry Penner Jr. was granted 26,000 non-qualified stock options.
Summary
- Harry Penner Jr., a Director at Celldex Therapeutics, Inc., was granted 26,000 non-qualified stock options.
- The options have an exercise price of $34.09 and were granted on June 25, 2026.
- These options are exercisable starting June 25, 2027, and expire on June 25, 2036.
- The grant is part of the company's 2021 Omnibus Equity Incentive Plan.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation practice for a director rather than a significant financial event or strategic shift.
Positives
- Director compensation through stock options aligns management interests with shareholder value.
- The grant of options suggests confidence in the company's future performance and stock appreciation potential.
Risks
- The value of the stock options is contingent on the future performance of Celldex Therapeutics' stock price.
- If the stock price does not exceed the exercise price of $34.09, the options may not be exercised profitably.
Future Outlook
The grant of stock options implies a positive outlook for the company's stock performance, as their value is tied to future stock price appreciation.
Industry Context
StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, used to attract, retain, and incentivize key leadership by aligning their financial interests with long-term shareholder value.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Incentive Plan | Grant of stock options under the 2021 Omnibus Equity Incentive Plan. | 06/25/2026 | Standard practice for director compensation, aimed at aligning incentives. |
Stakeholder Impact
- Shareholders: The alignment of director compensation with stock performance can be viewed positively, as it incentivizes management to drive shareholder value.
- Employees: The existence of an equity incentive plan can contribute to a culture of ownership and motivation across the company.
Next Steps
- Director Harry Penner Jr. may exercise the options between June 25, 2027, and June 25, 2036, provided the stock price is above the exercise price.
Key Dates
| Date | Description |
|---|---|
| 06/25/2026 | Date of grant of stock options. |
| 06/25/2027 | Earliest date the stock options become exercisable. |
| 06/25/2036 | Expiration date of the stock options. |
| 06/29/2026 | Date of filing of the statement. |
Keywords
Celldex Therapeutics, CLDX, Form 4, Stock Options, Director Compensation, Equity Incentive Plan, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.